Another example of the uncertainties, vagaries and potential disappointments of drug development following the failure of a therapy that was the subject of the largest-ever venture capital exit from an Australian company.
Latest Video
New Stories
-
Tour de Cure backs further development of Noxopharm's preclinical brain cancer candidate
April 24, 2024 - - Latest News -
Novartis nominates ex-BMS chief executive as its new chair
April 24, 2024 - - Latest News -
'The Pharmac system again, over about 33 years old, hasn’t really changed and evolved'
April 24, 2024 - - Latest News -
AusBiotech appoints experienced Sanofi leader as its new chief executive
April 23, 2024 - - Latest News -
Should principles such as 'equity' and 'opportunity cost' be applied consistently or not at all?
April 23, 2024 - - Latest News -
Rare Cancers Australia welcomes new appointments to its board of directors
April 23, 2024 - - Latest News -
BMS and Australian venture capital firm back immunotherapy company Pathios Therapeutics
April 23, 2024 - - Latest News